Topiramate — Wikipedia

Topiramate
Identification
UICPA name	Sulfamate de ((3AS, 5AR, 8AR, 8BS) -2,2,7-7-Tétméthyltétrahydro-3AH-Bis [1,3] Dioxolo [4,5-b: 4 ‘, 5’-D] pyran-3a -Yl] Méthyle
Synonyms	after-content-x4 Sulifamate 2, 4,5-besydy (1-Maryism)-Malimy-aretante).
N O CAS	97240-79-4
N O Echa	100.129.713
Code ATC	N03 AX11
DrugBank	AprD00237
Pubchem	5284627
SMILES	O1[C@]2([C@H]([C@H]3[C@H](OC(O3)(C)C)CO2)OC1(C)C)COS(N)(=O)=O Pubchem , 3D view
Inches	Inches: 3D view Inchi = 1/C12h21no8s/C1-10 (2) 18-7-5-16-12 (6-17-22 (13,14) 15) 9 (8 (7) 19-10) 20-11 (3, 4) 21-12/h7-9h, 5-6h2,1-4h3, (H2,13,14,15)/T7-, 8-, 9+, 12+/m1/s1
Chemicals
Formula	C twelfth H 21 NO 8 S   [Isomers]
Molar mass [ first ]	339,362 ± 0.019 G/MOL C 42,47 %, H 6,24 %, N 4,13 %, O 37,72 %, S 9,45 %,
Pharmacokinetic data
Bio -supplood	80%
Metabolism	30% liver, 70% is excreted unchanged
Half-life of élim.	19 to 11 p.m.
Excretion	70% renal (the form unchanged)
Therapeutic considerations
Administration	oral
IS units and CNTP , unless otherwise stated.
modifier

The topiramate is an antiepileptic drug used for generalized or partial type epilepsies. It is found, in France, under the name of Epitomax and in the United States, Canada, the United Kingdom, Australia and certain other countries under the name of Topamax.
It can also be used as a preventive treatment for migraine attacks.

Studies have also been carried out on its usefulness in the treatment of the effects induced by ketamine, then used as a model of schizophrenia.

Il Casiit a Durrivé du Frucstose ^{[ 2 ]} .

The bioavailability is more than 80%, without significant modification by food intake. Its half-life is around 24 hours and the excretion is renal. Phenytoin and carbamazepine halved its half-life, imposing an increase in doses ^{[ 3 ]} .

• Epilepsy
  Epilepsy of the child and adolescent. This is its first use. In children, it is indicated for the treatment of Lennox-Gastaut syndrome ^{[Ref. necessary]} .
• Migraines
  Furthermore, it significantly decreases the number of migraine crises when given in basic treatment ^{[ 4 ]} .
• Borderline personality disorder
  Borderline personality disorder including mood instability. This indication is recommended by a review of the 2010 Cochrane collaboration ^{[ 5 ]} .
• Bipolar disorder
  However, this indication is criticized by a Cochrane review which concludes in insufficient efficiency ^{[ 6 ]} .

Studies have also been carried out on its usefulness in treating the effects brought about by ketamine, then used as a model of schizophrenia ^{[ 7 ] , [ 8 ]} .

The most frequent are the tingling sensations (paraesthesia present in half of the cases and leading to stopping treatment in just less than one in 10) and a fairly significant loss of weight during treatment ^{[ 9 ]} .

The ANSM warns against the teratogenicity of the topiramate: pregnant women are exposed to a risk 3 times greater of fetus malformations, including Bacs-de-de-de-livre or hypospadias. In addition, cases of neurodevelopmental disorders are reported ^{[ ten ]} . The study Jama Neurology of May 31, 2022 brings new elements. The ANSM then modifies the prescription conditions mentioning that the observed risk of major malformations amounts to 8.2%, as well as the risk of the occurrence of autistic spectrum disorders which is between 2 and 6%, finally a risk of an intellectual impairment which located between 1 and 8%.